HLS Therapeutics Inc.

Latest

Jun 21, 2019, 12:40 ET HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 21, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in Toronto, Ontario. A...


Jun 05, 2019, 08:51 ET HLS Therapeutics Announces Closing of $50 Million Bought Deal Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, June 5, 2019 /CNW/ - ...


May 30, 2019, 06:30 ET HLS Therapeutics to Present at Two Upcoming Conferences

TORONTO, May 30, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that ...


May 14, 2019, 16:18 ET HLS Therapeutics Announces $43,500,000 Million Bought Deal Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ ETOBICOKE, ON, May 14, 2019...


May 09, 2019, 06:30 ET HLS Therapeutics Announces Q1 2019 Financial Results

Revenue of $13.2 million, Adjusted EBITDA of $8.3 million and Cash from Operations of $8.3 million Granted priority review status for Vascepa™ by Health Canada, which could reduce the review period...


Apr 29, 2019, 06:00 ET HLS Therapeutics Files New Drug Submission for Vascepa® in Canada

Cardiovascular disease is the leading cause of death globally1 NDS for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center cardiovascular outcomes study that showed ...


Apr 25, 2019, 06:30 ET HLS Therapeutics to Host Q1 2019 Financial Results Conference Call

TORONTO, April 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets,...


Apr 23, 2019, 06:30 ET HLS Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 23, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces...


Mar 29, 2019, 15:16 ET HLS Therapeutics Granted Priority Review Status from Health Canada for Vascepa®

Cardiovascular disease is the leading cause of death globally1 HLS New Drug Submission (NDS) for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center cardiovascular...


Mar 21, 2019, 06:30 ET HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

Revenue of $61.4 million, Adjusted EBITDA of $41.1 million and Cash from Operations of $32.7 million for the year-ended December 31, 2018 REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for...


Mar 19, 2019, 06:32 ET HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics Inc. ...


Mar 19, 2019, 06:30 ET HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established

TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces...


Mar 14, 2019, 06:30 ET HLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device

From a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One...


Mar 07, 2019, 06:30 ET HLS Therapeutics to Host 2018 Fourth Quarter and Year-End Financial Results Conference Call

TORONTO, March 7, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets,...


Feb 19, 2019, 06:30 ET HLS Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

TORONTO, Feb. 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces...


Feb 06, 2019, 06:30 ET HLS Therapeutics Announces Graduation to the Toronto Stock Exchange

TORONTO, Feb. 6, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, is...


Jan 29, 2019, 06:30 ET HLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange

TORONTO, Jan. 29, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets,...


Nov 15, 2018, 06:30 ET HLS Therapeutics Announces Q3 2018 Financial Results

REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for which HLS has in-licensed exclusive Canadian rights, exceeded primary endpoint demonstrating an approximately 25% relative risk reduction...


Nov 12, 2018, 06:30 ET HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular

Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35% Hospitalization ...


Nov 01, 2018, 06:30 ET HLS Therapeutics to Host 2018 Third Quarter Results Conference Call

TORONTO, Nov. 1, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will...


Sep 24, 2018, 05:30 ET HLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint

REDUCE-IT is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific to...


Sep 06, 2018, 06:30 ET HLS Therapeutics Appoints Tim Hendrickson as CFO

TORONTO, Sept. 6, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular...


Aug 22, 2018, 18:08 ET HLS Therapeutics Announces Grant of Stock Options

TORONTO, Aug. 22, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular...


Aug 15, 2018, 06:30 ET HLS Therapeutics Announces Q2 2018 Financial Results

Revenue of $16.3 million, Net Loss of $0.6 million and Adjusted EBITDA of $11.0 million, which were all in line with expectations Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon...


Jul 30, 2018, 06:30 ET HLS Therapeutics to Host 2018 Second Quarter Results Conference Call

TORONTO, July 30, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will...